Research programme: amyotrophic lateral sclerosis gene therapy - Janus/Ferrer/Bioingenium
Latest Information Update: 04 Nov 2017
At a glance
- Originator Universitat Autonoma de Barcelona; University of Zaragoza
- Developer BioIngenium; Ferrer; Janus Developments
- Class Gene therapies
- Mechanism of Action Apoptosis inhibitors; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in Spain (IM)
- 12 Mar 2014 Preclinical development is ongoing in Spain
- 16 Nov 2010 Janus Developments, Ferrer and Bioingenium collaborate to develop tetanus toxin fragment gene therapy for Amyotrophic lateral sclerosis